n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, March 16th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

Royale Energy, Inc. (ROYL)

Wall Street Resources, Investing Futures, WealthMakers, Turn Key Oil, Stock Analyzer, Microcapmillionaires, Jason Bond, SmallCapVoice, Marketbeat, SmarTrend Newsletters, and Oakshire Financial reported previously on Royale Energy, Inc. (ROYL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Royale Energy, Inc. centers on the acquisition, development, and marketing of natural gas and oil. It owns and operates wells in the Sacramento and San Joaquin basins in California and has royalty interests in Alaska. The OTCQB-listed Company engages in the production and sale of natural gas; the acquisition of oil and gas lease interests and proved reserves; the drilling of exploratory and development wells; and the sale of fractional working interests in wells to undergo drilling. An independent exploration and production company, Royale Energy is based in El Cajon, California.

The Company has properties covering greater than 20,000 acres in California and nine 3D seismic surveys in the Sacramento Basin. At present, Royale Energy operates more than 60 natural gas wells to date. It owns interests in 12 natural gas fields in California. On February 4, 2014, Royale’s Cardiff well went into production.

Royale has its Lonestar Field. It includes in excess of 1,000 acres. The Lonestar Field has produced over five billion cubic ft. of gas from five separate Forbes sandstone reservoirs. The Lonestar Field includes the Goddard 7-1 Well; the Goddard #2 and Goddard #3 (offset wells to the Goddard 7-1); and the Magnum Well.

Royale Energy’s North Arbuckle is in Colusa County in the Sacramento Basin. Currently, this is the most active area for the Company. It has 10 producing natural gas wells, which have produced more than 5 billion cubic ft.

The Company’s plan is to drill many more in the next couple of years.
Royale has acquired more than 96,000 acres on the Alaskan North Slope. The acreage spans over 88 miles east and west of the Trans-Alaska pipeline route.

Furthermore, Royale Energy’s Victor Ranch Field is in Tehama County, in the Northern Sacramento Basin. This field has been producing natural gas for the Company since it drilled its first well there in 1993.

Royale Energy has an agreement with a major independent exploration and development company to expand its joint development agreement in the Sacramento Basin of Northern California. The expanded arrangement encompasses roughly 1,900 acres in the Rio Vista Gas Field. Royale will target the Capay and Martinez sands.

Previously, Royale Energy and privately held Matrix Oil Management Corporation entered into a Letter of Intent (LOI) to merge in a combined stock and assumption of debt transaction. Royale Energy announced that on February 14, 2017, Royale Energy Holdings, Inc. (Royale Holdings), filed a registration statement on Form S-4 with the Securities and Exchange Commission (SEC) for a proposed merger between Royale Holdings, Royale, and Matrix Oil Management Corporation and its affiliates.

Last week, Royale Energy and Matrix Oil Management Corporation jointly announced the closing and completion of the merger between Royale and Matrix. This merger transaction was approved by the Matrix and Royale Energy shareholders on November 16, 2017. It closed after the companies received the consent of Matrix’s lender, Arena Limited SPV, LLC.

The completion of this strategic transaction creates a high-growth California-focused operating company. It has an Executive Team experienced in raising accretive capital and acquiring, operating, and developing successful oil and gas projects.

According to an internal reserve report, as of December 31, 2016, Matrix had proved reserves of 9.1 million barrels of oil equivalent (BOE) (84 percent oil) with a PV10 value of $58.8 million based on SEC pricing. Matrix Oil has oil and gas properties in the Sacramento, San Joaquin, and Los Angeles Basins of California and the Permian Basin of Texas.

Royale Energy, Inc. (ROYL), closed Friday's trading session at $0.44, up 6.02%, on 16,450 volume with 11 trades. The average volume for the last 60 days is 17,731 and the stock's 52-week low/high is $0.316/$0.629.

MRI Interventions, Inc. (MRIC)

Wall Street Resources, Real Pennies, and FeedBlitz reported earlier on MRI Interventions, Inc. (MRIC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

MRI Interventions, Inc. is a commercial stage medical device company. It develops and commercializes distinct platforms for performing minimally invasive surgical procedures in the brain under direct, intra-procedural Magnetic Resonance Imaging, or MRI, guidance. Using a hospital's existing MRI suite, the design of its Food and Drug Administration (FDA)-cleared and CE-marked ClearPoint® system is to enable a range of minimally invasive procedures in the brain. Listed on the OTCQB, MRI Interventions has its headquarters in Irvine, California.

The Company’s emphasis is Magnetic Resonance Imaging (MRI)-Guided Neurosurgical procedures. The ClearPoint® system enables real-time MRI-guided navigation for a wide assortment of minimally-invasive neurosurgery procedures.

The platform is especially well-matched for facilitating drug delivery directly to brain tumors. The ClearPoint® system is the only navigation platform designed to allow real-time visualization during minimally-invasive neurosurgical procedures.

MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, regarding the ClearPoint® system. Furthermore, MRI Interventions is developing the ClearTrace® system in partnership with Siemens Healthcare. This is to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation.

ClearPoint® is an integrated system of hardware components, disposable components, and intuitive, menu-driven software. The ClearPoint® system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite. ClearPoint® procedures can be used with 1.5T and 3T scanners.

Earlier this month, MRI Interventions announced the first brain tumor surgery in Minnesota performed utilizing the ClearPoint® Neuro Navigation System at the University of Minnesota Medical Center. University of Minnesota Health represents collaboration between University of Minnesota Physicians, Fairview Health Services, and University of Minnesota Medical Center.

This week, MRI Interventions commented on Voyager Therapeutics’ announcement of FDA clearance of its Investigational New Drug (IND) application for VY-AADC. This is Voyager’s gene therapy program targeting advanced Parkinson’s disease. Clearance of the IND permits Voyager Therapeutics to formally start clinical trial sites and commence screening patients for its pivotal Phase 2-3 program.

Wendelin Maners, Vice President of Marketing and Clinical Operations at MRI Interventions, said, “We are excited that FDA cleared this IND, allowing commencement of Voyager’s gene therapy pivotal program for advanced Parkinson’s disease. This represents an important milestone in our own pipeline of gene therapy and drug delivery trials utilizing the ClearPoint® Neuro Navigation system and SmartFlow® drug delivery cannulas as the premier targeting platform for direct deployment of biologics to precise regions within the brain.”

MRI Interventions, Inc. (MRIC), closed Friday's trading session at $3.10, up 1.64%, on 14,853 volume with 24 trades. The average volume for the last 60 days is 18,128 and the stock's 52-week low/high is $1.76/$7.40.

Liberty One Lithium Corp. (LRTTF)

OTC Markets, 4 Traders, ProcativeInvestors, and MarketWatch reported on Liberty One Lithium Corp. (LRTTF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Liberty One Lithium Corp. is a developing exploration company headquartered in Vancouver, British Columbia. It focuses on the acquisition and development of high grade lithium brine deposits. Lithium is an important component of batteries, which power everything from cars to smartphones, laptops, and power tools. The Company sees lithium as an opportunity to participate in the diversification and continued growth (and protection) of a strong international energy policy. Liberty One Lithium lists on the OTC Markets’ OTCQB.

The Company’s initial prospects are in Argentina’s “Lithium Triangle” and Utah’s Paradox Basin. They are situated in historic sources of high grade lithium-bearing brines. Historic resource indicates potential to produce large volumes of brine on-site.

In Argentina, Liberty One Lithium’s Pocitos West prospect comprises more than 39,000 acres (15,857 Ha) in the middle of the well-known lithium triangle. It is in the Pocitos Salar, Los Andes Department, Western Salta Province, Argentina.

In Utah, the Company’s North Paradox property comprises 233 placer claims covering 4,480 acres located upon the Paradox Basin in Grand County, Utah, 15 kilometers west of the town of Moab, in southeastern Utah.

In June of 2017, Liberty One Lithium announced the closing of a mineral option and joint venture (JV) agreement with Millennial Lithium Corp. (Vancouver, British Columbia). The agreement grants Liberty One Lithium the sole and exclusive right and option to acquire up to an 80 percent undivided beneficial right, title, and interest in the Pocitos West project in Argentina.

In mid-December 2017, Liberty One Lithium announced the activation of plans to speed up activities at the Company’s flagship "North Paradox" property in Grand County, Utah. The presence of the Cane Creek mine immediately southeast of Liberty One Lithium’s property that has been producing potash for more than 45 years demonstrates the efficacy of production processes alike to those envisaged for the mining of lithium in the area.

Liberty One Lithium earlier affirmed 2018 plans to start an evaluation of its promising “North Paradox” property within the Paradox Basin in Grand County, Utah. Log data at the Utah Geological Survey library indicates the area appears rich with supersaturated brines. In addition, nearby long-term mine operations effectively demonstrate the climatic efficacy for traditional evaporative production processes.

Liberty One Lithium Corp. (LRTTF), closed Friday's trading session at $0.349, up 24.64%, on 460,387 volume with 182 trades. The average volume for the last 60 days is 524,119 and the stock's 52-week low/high is $0.2746/$1.95.

Inspyr Therapeutics, Inc. (NSPX)

BUYINS.NET and Zacks reported earlier on Inspyr Therapeutics, Inc. (NSPX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company based in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients’ with numerous different tumor types. Inspyr Therapeutics’ team has considerable pharmaceutical industry and scientific experience.

The Company lists on the OTC Markets Group’s OTCQB. It previously went by the name GenSpera, Inc. It changed its name to Inspyr Therapeutics, Inc. in August of 2016.

Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.

Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). In addition, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.

Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program centers on the treatment of gastric cancer.

Inspyr has started a preclinical study in gastric cancer PDX tumor models that express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.

Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. This unique platform technology has the potential to work across a range of drugs that precisely target different cancers.

In October of 2017, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.

Inspyr Therapeutics, Inc. (NSPX), closed Friday's trading session at $0.03, up 50.00%, on 4,266 volume with 2 trades. The average volume for the last 60 days is 40,632 and the stock's 52-week low/high is $0.015/$0.55.

Adama Technologies Corporation (ADAC)

StreetInsider, InvestorsHub, OTC Markets, Morningstar, and Stockhouse reported on Adama Technologies Corporation (ADAC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Adama Technologies Corporation is a Venture Capital Company listed on the OTCQB. It owns, operates, and invests in technology companies and also startups and expansion companies. The Company has a hands-on approach and works to develop the management and leaders around the corporate landscape to transform big ideas into game changing execution in the field. Adama Technologies has its corporate office in Henderson, Nevada.

Adama Technologies has exceptional access to equity lines of credit, equity funds, private investors, incubators, mentor partners and close ties with Fortune 100, 500 and 1000 companies who serve as exit strategies for many of Adama’s investments.

Adama Technologies’ portfolio companies include Alpine Industries and SafeGuard Pii. Its flagship investment is Alpine Industries located in Utah. Alpine specializes in machining and aerospace manufacturing.

This investment and acquisition launches Adama Technologies into the fast expanding field of aerospace technology. Furthermore, it positions Adama with the stability of being a defense contractor for the U.S. military.

Since its establishment in 1974, Alpine Industries has manufactured several hundred aerospace landing gear components and other spare parts. It continues to work as a US government contractor.

Presently, Alpine holds more than 15 US Military contracts. Most of these contracts are with the US Air Force. Alpine Industries also manufactures parts for a number of private companies. These include parts for drilling components utilized in oil and water wells, roller-coasters, motorcycles, zip line parts, crash pads, as well as drilling carts.

SafeGuard Pii is an industry pioneer and top-tier Privacy Management Firm. It provides compliance solutions to companies across the United States. In addition, SafeGuard Pii is the provider of a strong identity theft protection and restoration product.

The Company’s PII Defender program monitors internet black market sites, other internet trading sites where ID thieves buy and sell information, utility and phone records, public databases, criminal databases and DMV records, plus credit files for one’s personal information.

This week, Adama Technologies announced that it was accepted and successfully up-listed to the OTCQB marketplace with OTC Markets. Adama had outlined a course towards growth and development. This path included development of additional revenue streams, growing revenues within their present operations, and up-listing into the QB Marketplace.

In addition, this week, Adama Technologies announced that the Company will bid on an additional $3,000,000 in new government contracts with at least $2,000,000 of that number being for US Military Defense contracts. Adama detailed its month-of-March bidding plan and strategy and its optimism concerning its ability to win these contracts. As the bidding process is underway, Adama Technologies will continue to look for additional revenue opportunities in its commercial and retail outlets.

Adama Technologies Corporation (ADAC), closed Friday's trading session at $0.069, up 7.81%, on 2,193,455 volume with 129 trades. The average volume for the last 60 days is 1,459,646 and the stock's 52-week low/high is $0.011/$0.3732.

Natcore Technology, Inc. (NTCXF)

Stockhouse, InvestorsHub, MarketWatch, OTC Markets, Business Insider, and StreetInsider reported on Natcore Technology, Inc. (NTCXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Natcore Technology, Inc. concentrates on using its proprietary Foil Cell technology to considerably lower the costs and improve the power output of solar cells. The Company is creating the next generation of solar cells. Natcore is developing two main technologies. These are low-cost, all-back-contact solar cell structures, and Black Silicon cells.

A solar R&D company, Natcore Technology is headquartered in Rochester, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s Foil Cell (All Back Contact Solar Cell) uses a high-speed, low temperature laser process. Natcore’s Black Silicon technology streamlines the path to low solar cell reflectance.

Natcore Technology has its Natcore Laboratory in Rochester. This is a 19,000 sq. ft. facility. It has 8,000 sq. ft. of ‘class 10,000’ clean room. The Company engages in the full solar cell process at this laboratory - from bare silicon wafer to working cells.

Regarding the Company’s Foil Cell Structure, the process involves multilayer foil metallization. Key features/properties include low cost contact metals and simplified manufacture. This includes low capital equipment cost, small factory footprint, and low temperature processing.

Natcore Technology has established exclusive licenses and/or joint research agreements with Rice University, the National Renewable Energy Laboratory (NREL), Fraunhofer ISE and the University of Virginia. The Company has received 33 patents; 32 patents are pending.

Yesterday, Natcore Technology announced it significantly streamlined the fabrication method for its pioneering Natcore Foil Cell™. This allows for even lower-cost production methods.

The Company is targeting greater than 25 percent real-world efficiency for its eventual production solar cells. This is approximately a 25 percent performance improvement over numerous high-end commercial cells being installed today.

The use of laser processing to create the Company’s unique, all-back-contact cell structure has been eliminated and replaced by a carrier selective contact process. This is combined with a foil metallization, which can be inexpensively made with high-speed roll-processing methods. Natcore has started an accelerated development program to produce a prototype with the new process, and also include production cost and efficiency modeling by independent authorities.

Natcore Technology, Inc. (NTCXF), closed Friday's trading session at $0.1643, up 2.69%, on 1,514,823 volume with 240 trades. The average volume for the last 60 days is 123,467 and the stock's 52-week low/high is $0.0351/$0.20.

Kalytera Therapeutics, Inc. (KALTF)

Stockhouse, Stockwatch, The Street, OTC Markets, InvestorsHub, Dividend Investor, and Investing reported on Kalytera Therapeutics, Inc. (KALTF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

A clinical-stage pharmaceutical company, Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics. It is working to establish a leading position in the development of novel cannabinoid medicines for a spectrum of important unmet medical needs, with an initial concentration on Graft versus Host Disease (GvHD). Kalytera Therapeutics has its U.S. headquarters in Novato, California and its research facility in Israel.

GvHD is a multisystem disorder. It is a common, life-threatening complication of hematopoietic stem cell transplant (HCT) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs. This includes the skin, gastrointestinal tract, liver, lungs, and eyes.

Additionally, Kalytera Therapeutics is developing a new class of proprietary cannabidiol (CBD) therapeutics. The Company’s intention is to file composition of matter and method of use patents covering its novel inventions. Its intention is to explore the use of CBD, a non-psychoactive cannabis constituent.

Kalytera is working to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. Moreover, the Company will focus on orphan conditions, with the aim of generating data in humans that may support follow-on studies in major conditions.

Kalytera Therapeutics has received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel. This is to commence a Phase 2 study to evaluate cannabidiol (CBD) for the prevention of GvHD. The proposed study is a Phase 2, open label, multicenter trial.

This trial is to evaluate the pharmacokinetic profile, safety, and efficacy of multiple doses of CBD for the prevention of GvHD following allogeneic hematopoietic cell transplantation (HCT). The proposed study will take place at the Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa, in Israel.

This past November, Kalytera Therapeutics announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for US Patent Application 15/143,694 covering the use of cannabidiol (CBD) in the treatment of graft versus host disease (GVHD).

Mr. Robert Farrell, J.D., Kalytera Therapeutics’ Chief Executive Officer, said in November, "…There are currently few options to treat persons with GVHD, a critically underserved market. The results of the previous four clinical studies that evaluated CBD in the prevention and treatment of GVHD were exceptional and unprecedented. Based on that data, we believe that our proprietary CBD based therapeutic may provide a major advance in the prevention and treatment of this disease, and we anticipate that we will also soon receive Notice of Allowance for our US Patent Application 14/787,515 that covers both the use of CBD in the prevention of graft versus host disease, and the treatment of graft versus host disease.”

Kalytera Therapeutics, Inc. (KALTF), closed Friday's trading session at $0.2233, down 2.79%, on 21,350 volume with 10 trades. The average volume for the last 60 days is 120,253 and the stock's 52-week low/high is $0.06/$0.4544.

MMEX Resources Corp. (MMEX)

InvestorsHub, Hydrocarbonprocessing, MarketWatch, Stockhouse, and OTC Markets reported on MMEX Resources Corp. (MMEX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MMEX Resources Corp. centers on the acquisition, development and financing of oil, gas, refining and infrastructure projects in Texas, Peru, and other countries in Latin America. A development-stage company, MMEX formed to engage in the exploration, extraction, refining and distribution of oil, gas, petroleum products and electric power. Established in the U.S. in 2010, MMEX Resources is based in Fort Stockton, Texas.

The Company’s principal areas of interest include the acquisition and potential development of refining, oil & gas assets in Texas, and the acquisition of oil and gas properties in Peru. Principal areas of interest also include crude, oil and product export opportunities in Latin America, and the development of terminals, storage, refining, oil & gas in Brazil.

The Company’s projects include the Pecos County Refinery Project, Fort Stockton, Texas. Phase 1 of the project is a 10,000 BPD Crude Distillation Unit. Phase 2 is a 100,000 BPD Large-Scale Refinery. This project is in Sulfur Junction, which is roughly 20 miles northeast of Fort Stockton. This project is strategically positioned close to oil production in West Texas, with storage capability.

MMEX Resources announced in August of 2017 that it secured permit approval from the Texas Commission on Environmental Quality (TCEQ) to build a 10,000 barrel-per-day (BPD) crude distillation unit near Fort Stockton, Texas. The expectation is that the project will require approximately 12 months of construction time and create major economic impact in Pecos County.

Last month, MMEX Resources announced that it retained Interstate Treating, Inc. (Odessa, Texas) to be the primary contractor for the engineering, procurement and construction of MMEX’s planned 10,000 barrel-per-day (bpd) crude oil distillation unit in Pecos County.

The Company also announced that Interstate Treating’s field personnel would immediately start the detailed engineering phase of the project so that the parties can finalize a definitive engineering, procurement and construction (EPC) agreement. Interstate Treating is a foremost provider of complete turnkey construction services to the gas treating and processing industry.

This week, MMEX Resources announced that it signed an off-take agreement with Pilot Thomas Logistics. This off-take agreement is for the sale of its diesel fuel production from Phase 1 of the MMEX refinery project in Pecos County, a 10,000 BPD Crude Distillation Unit. This agreement provides for Pilot Thomas Logistics to obtain 100 percent of the diesel production from Phase 1, around 4,200 barrels per day, for markets in the Permian Basin region chiefly for use in drilling operations.

MMEX Resources held a ground breaking ceremony on its 10,000 barrel-per-day (BPD) crude distillation unit near Fort Stockton, Texas on Friday, November 17, 2017.

MMEX Resources Corp. (MMEX), closed Friday's trading session at $0.0046, up 4.55%, on 10,484,432 volume with 85 trades. The average volume for the last 60 days is 11,678,570 and the stock's 52-week low/high is $0.0031/$0.0563.

Helix TCS, Inc. (HLIX)

Market Exclusive, GreenMarketReport.com, The Stock Rover, The Daly Marijuana Observer, Marketwired, Simply Wall St, Business Insider, Stock Daily Review, and The Street reported on Helix TCS, Inc. (HLIX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Helix TCS, Inc. is a provider of integrated operating environment solutions for the legal cannabis Industry. The Company has acquired Cannabase, which is the oldest and largest wholesale platform in the cannabis industry. Helix TCS’ mission is to provide clients with the most powerful and inventive integrated operating environments in the market. This is to help clients better manage and lessen risk while they concentrate on their core business. OTCQB-listed, Helix TCS is based in Greenwood Village, Colorado.

The Company’s team consists of former military, law enforcement, and technology professionals. These have significant experience in security and law enforcement, intelligence, technology design and development, partner relations, data aggregation, venture capital, private equity, risk-management, banking, and finance.

Helix TCS’ services include Technology, Compliance, and Security. It offers a technology platform that allows clients to manage inventory and supply costs by way of Cannabase.

Regarding Compliance, the Company has a wide range of compliance services for companies in the Cannabis Industry. This safeguards clients’ ability to operate while increasing their access to services.

Concerning Security, Helix TCS offers Transport, Armed and Unarmed Guarding, Training, Investigation, as well as Special Services. Security is the Company’s flagship service offering.

In June of 2017, Helix TCS announced its acquisition of Security Grade Protective Services, Ltd. Security Grade now operates as a wholly-owned subsidiary of Helix TCS. Security Grade is a Denver, Colorado-headquartered security firm. It provides a range of custom, full-service security solutions to cannabis business customers.

Security Grade has a strong concentration on surveillance technology. This acquisition allows Helix TCS to continue to expand its family of operating solutions with a number of services. These services include Information Technology (IT) security, building fortification, private investigations, and advanced video surveillance programs and software.

Helix TCS reported Revenue that increased in Q3 2017 85 percent from the previous year Q3, to $1,129,746. This was propelled by a major increase in the Company’s number of clients and also a full quarter of revenue from its Security Grade acquisition.

Helix TCS, Inc. (HLIX), closed Friday's trading session at $3.45, up 38.00%, on 98,146 volume with 302 trades. The average volume for the last 60 days is 13,217 and the stock's 52-week low/high is $0.75/$13.00.

graphic

The QualityStocks
Company Corner

graphic
graphic

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.039, up 20.93%, on 932,469 volume with 81 trades. The stock’s average daily volume over the past 60 days is 598,705, and its 52-week low/high is $0.0161/$0.12.

Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation that specializes in state-of-the-art financial services structured to serve the medical cannabis and banking industry, announced today that state licensed marijuana establishments may sign up via its website for its banking and financial processing system.  The company, which has been working with targeted establishments, has now made its services available to the entire industry.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions Fully Launches Payment System, Establishments May Now Enroll

NetworkNewsBreaks – Medical Cannabis Payment Solutions (REFG) Delivers Innovative Solutions to Cash-handling Issues in the Cannabis Industry

Medical Cannabis Payment Solutions’ (REFG) Green is Designed to Grow

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.70, up 6.25%, on 234,712 volume with 281 trades. The stock’s average daily volume over the past 60 days is 768,635 and its 52-week low/high is $0.6171/$3.2929.

ABcann Global Corporation (TSXV:ABCN) (Frankfurt:23Q) (OTC:ABCCF) announced that Ken Clement, ABcann's founder and director, has resigned from the Board of Directors.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABCann Announces Resignation of Founding Director Ken Clement

Preventive Medical Solutions Integrate with Major Cannabis Providers for Innovative Drug Delivery

ABcann Retains VIRTUE as Agency of Record

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $1.26, up 2.44%, on 52,507 volume with 88 trades. The stock’s average daily volume over the past 60 days is 131,092, and its 52-week low/high is $0.47/$2.70.

EVIO, Inc. (OTCQB: EVIO), a life sciences and cannabis testing company, has set up in California to address the supply shortfall in cannabis testing services. To view the full article, visit: http://cnw.fm/1q0YK.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

CannabisNewsBreaks – EVIO, Inc. (EVIO) Set to Profit from Shortage of Testing Services as California’s Mandatory Cannabis Testing Deadline Approaches

EVIO, Inc. (EVIO) on Track for Exponential Growth within the Booming Legal Cannabis Industry

NetworkNewsBreaks – EVIO, Inc. (EVIO) Invests $800,000 in New Laboratory Equipment at Two Cannabis Testing Facilities

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0595, up 1.54%, on 1,828,408 volume with 153 trades. The stock’s average daily volume over the past 60 days is 8,584,946, and its 52-week low/high is $0.0132/$0.415.

Specialized holding company SinglePoint, Inc. (OTCQB: SING) was a featured company on this week’s episode of MoneyTV with Donald Baillargeon. To view the full interview, visit: http://nnw.fm/m7kFX. To view the full press release, visit: http://nnw.fm/3jjvL.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

CannabisNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Roth Capital Conference on MoneyTV

SinglePoint Inc.’s (SING) Launch of Cannabis Payment Solution Covered by NetworkNewsAudio

CannabisNewsBreaks – SinglePoint, Inc. (SING) Updates Shareholders with Third Episode of Video Series

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P)

The QualityStocks Daily Newsletter would like to spotlight Liberty Leaf Holdings Ltd. (LIBFF). Today, Liberty Leaf Holdings Ltd. closed trading at $0.349, up 1.78%, on 16,091 volume with 9 trades. The stock’s average daily volume over the past 60 days is 149,631, and its 52-week low/high is $0.0091/$0.8074.

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P), a vertically-integrated cannabis company with strategic investments in proven, revenue-generating businesses, is building a diversified portfolio that includes marketing a wide range of high quality, medicinal grade cannabis products with tremendous promise for both human and veterinary use. Liberty Leaf and its wholly owned subsidiary, North Road Ventures, recently signed an agreement with Cannabis Compliance Inc. (“CCI”) to establish Good Manufacturing Practice (GMP)-compliant processes and procedures in producing its finished products (http://cnw.fm/k9W56).

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF), is a publicly traded Canadian-based company with strategic investments in businesses that are established, revenue- producing players in the medicinal and recreational cannabis market. Liberty Leaf’s focus is to build and support a diversified portfolio of cannabis-sector businesses, including those involved in the cultivation and processing of legal medicinal and recreational cannabis, value-added CBD/THC pet products, and supply-chain products for this dynamic and fast-growing sector. Liberty Leaf provides funding, management, HR resources and marketing expertise to help companies thrive and accelerate growth.

Liberty Leaf’s leading investments to date include:

  • North Road Ventures – An emerging end-to-end distributor of cultivated and manufactured cannabis products to licensed legal retailers. North Road has updated its application for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license to be distribution/sales-focused, making the company unique in the crowded field of other cultivation-based applicants. This forward-thinking initiative will help fulfill the anticipated increase in Canada’s recreational cannabis space once legalization takes effect in mid-2018. The submission includes a boost in product-vault capacity that will result in a five-fold increase in products available for distribution. Cannabidiol (CBD)-oil products are expected to account for 50 percent or more of projected sales.
  • Just Kush Enterprises – Liberty Leaf holds a 60 percent interest in Just Kush, a cultivator of premium, proprietary cannabis strains selected for different levels of CBDs and THCs. Just Kush’s cultivation facility is located near Oliver, British Columbia, and it currently controls a facility which holds a Medical Marihuana Access Regulations (MMAR) license. The company is also a late-stage applicant for an ACMPR license (Access to Cannabis for Medical Purposes Regulations), which will enable Just Kush to produce cannabis for the medicinal and recreational market.

Liberty Leaf is also an active partner with the following companies:

  • ESEV R&D – A privately owned, medical marijuana research and development company based in New York with clinical laboratories located in Israel. ESEV R&D, in collaboration with a leading clinical research organization in Israel, has launched a one-of-a-kind service for North American medical cannabis companies to organize and oversee clinical trials seeking to demonstrate the efficacy of medical cannabis products for specific medical conditions. Liberty Leaf has a three-year collaborative agreement with ESEV. Under that agreement, ESEV is researching the efficacy of CBDs in pets, with the 1st formulation trial targeting canine osteoarthritis, a medical condition that includes: hip dysplasia; elbow dysplasia; and hind-knee, also known as stifle, degenerative joint disease (DJD).
  • Blox Labs Inc. – A boutique technology company focused on creating best-in-class smartphone apps and software solutions driven by emerging trends in blockchain, smart contracts and decentralized application technologies. Liberty Leaf and Blox Labs are developing “cannaBLOX,” a blockchain-based smart contract supply chain management platform for the legalized cannabis industry.

The company’s management team is led by President and Director William Rascan who has 25-plus years in the investment brokerage industry, most recently as a partner, senior investment advisor with Northern Securities. Rascan’s business experience ranges from active international trading clients to raising capital for junior mining companies on the TSX Venture Exchange.

Rascan is joined by CFO Jamie Robinson, a chartered accountant who specializes in accounting, auditing, and financial reporting under both IFRS and ASPE. Prior to joining Liberty Leaf, Robinson worked at Deloitte as a manager focused on publicly listed and private company audits, business review, performance enhancement engagements and restructuring proceedings.

Steven Feldman, who has more than 25 years of experience in the capital markets and was part of the original management team of SouthGobi Resources; and Doug Macdonell, a retired RCMP officer and recognized expert in the field of cannabis and cultivation, serve as company directors. Dr. Robert Jackman, who has worked closely with multiple clients in the medical cannabis and Natural and Non-prescription Health Products (NNHP) industries in North America, was recently appointed as scientific project manager/fulfillment.

Liberty Leaf’s advisory board includes international lawyer, writer and speaker Robert W.E. Laurie; Barinder Rasode, who currently serves as CEO of the National Institute for Cannabis Health & Education (NICHE); and Dr. Mary C. Fitzpatrick, B.S., D.V.M., whose primary focus is on helping companion animals live pain free in their senior years. Disclaimer

Liberty Leaf Holdings Ltd. Company Blog

Liberty Leaf Holdings Ltd. News:

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Readies Niche Products for Legal Cannabis Industry

NetworkNewsBreaks – Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) and Blox Labs, Inc. (CSE: BLOX) (OTC: BLLXF) Complete Preliminary Input and Analysis in Phase One Development of cannaBLOX

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) Continues to Capitalize on the Burgeoning Legal Marijuana Markets

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.3342, off by 1.71%, on 74,466 volume with 24 trades. The stock’s average daily volume over the past 60 days is 20,450, and its 52-week low/high is $0.01/$0.80.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the incorporation of its first Australian wholly owned subsidiary, PreveCeutical (Australia) Pty Ltd. To view the full press release, visit: http://nnw.fm/7qdJ5. Also today, NetworkNewsAudio announces the Audio Press Release (APR) titled "Preventive Medical Solutions Integrate with Major Cannabis Providers for Innovative Drug Delivery," featuring PreveCeutical Medical. To hear the NetworkNewsAudio version, visit http://nnw.fm/4MoPC. To read the original editorial, visit http://nnw.fm/mV7JH.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Incorporates Australian Subsidiary

NetworkNewsAudio Announces Audio Press Release (APR) on PreveCeutical Medical Inc. Making Bold Advances in Preventative Medicine

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Secures Australian Importation Permit in Support of Research into Sol-gels

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0176, off by 2.76%, on 5,528,223 volume with 136 trades. The stock’s average daily volume over the past 60 days is 11,570,291, and its 52-week low/high is $0.0141/$0.16.

NetworkNewsAudio announces the Audio Press Release (APR) titled "Enterprise Blockchain Solutions Emerging in Cross-Industry Sectors," featuring Global Payout, Inc. (OTC Pink: GOHE). To hear the NetworkNewsAudio version, visit http://nnw.fm/fp9Iq. To read the original editorial, visit http://nnw.fm/12Jgu.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

NetworkNewsAudio Announces Audio Press Release (APR) on Global Payout, Inc. Banking on Nascent Blockchain Technology

"Banking the UnbankableTM": MoneyTrac Soft Launches MTRAC, a Full Service Banking Solution for Cannabis

Global Payout Inc. (GOHE) Subsidiary’s Public Initial Blockchain Offering Showcases Company’s Fintech Capabilities

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF)

The QualityStocks Daily Newsletter would like to spotlight Global Hemp Group, Inc. (GBHPF). Today, Global Hemp Group, Inc. closed trading at $0.1241, up 3.42%, on 97,826 volume with 48 trades. The stock’s average daily volume over the past 60 days is 386,851, and its 52-week low/high is $0.0115/$0.316.

Hemp cultivation company Global Hemp Group (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is on a mission to capture cash flow, generate revenues and create value for its shareholders through the execution of joint ventures, partnerships, and acquisitions. To view the full article, visit: http://nnw.fm/5IQhv.

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Hemp Group, Inc. Company Blog

Global Hemp Group, Inc. News:

NetworkNewsBreaks – Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Plans to Progress in Industrial Hemp Sector through Strategic Partnerships, Acquisitions

Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Completes $1.5 Million Private Placement

Building a Portfolio of Industrial Hemp Companies is Key to the Future of Global Hemp Group, Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF)

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $1.26, off by 3.82%, on 225,919 volume with 337 trades. The stock’s average daily volume over the past 60 days is 342,359 and its 52-week low/high is $0.27/$2.54.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Generate up to 80% of Revenues from Technology Licensing

Lexaria Begins Nicotine Absorption Study

Lexaria Bioscience Corp. Completes Successful Skin Absorption Study

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

BUYINS.NET
(AMTX) +118.75%

2.

QualityStocks
(NSPX) +50.00%

3.

Trader Power News
(SEED) +27.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251